| Accession |
PRJCA024918 |
| Title |
FLAME ctDNA |
| Relevance |
Medical |
| Data types |
EGFR mutation result data from tissue and plasma
|
| Organisms |
Homo sapiens
|
| Description |
This is a prospective, randomised, open-label, positive-controlled study to investigate the efficacy and safety of Osimertinib plus Carboplatin/Pemetrexed versus Osimertinib monotherapy in locally advanced or metastatic EGFRm NSCLC patients with EGFRm persistence in ctDNA at 3 weeks after first-line therapy with Osimertinib. |
| Sample scope |
Multiisolate |
| Release date |
2024-04-03 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Other
|
|
N/A
|
|
|
|
| Submitter |
Jie
Wang (zlhuxi@163.com)
|
| Organization |
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission date |
2024-04-03 |
